lactose has been researched along with Pseudomonas Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, F; Guo, DS; Hu, B; Hu, XY; Hu, Y; Li, HB; Li, JJ; Wang, KR; Wang, W; Xu, H; Zhang, X | 1 |
| Britton, WJ; Chan, HK; Chang, RYK; Kutter, E; Li, J; Lin, Y; Morales, S | 1 |
| Britton, W; Chan, HK; Chang, RY; Kutter, E; Li, J; Mathai, A; Morales, S; Wong, J | 1 |
| Kim, J; Kim, JW; Kim, YJ | 1 |
| Cao, Z; Chen, X; Dai, X; Guo, Q; Li, C; Wei, X; Yu, Y; Zhang, X; Zhao, Y | 1 |
| GRAY, FJ; KIDD, EE | 1 |
| Dale, RM; Schnell, G; Wong, JP | 1 |
7 other study(ies) available for lactose and Pseudomonas Infections
| Article | Year |
|---|---|
Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Ciprofloxacin; Delayed-Action Preparations; Diabetes Mellitus; Drug Delivery Systems; Humans; Hypoxia; Lactose; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Ulcer | 2022 |
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bacteriophages; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Dry Powder Inhalers; Excipients; Humans; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2019 |
Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
Topics: Aerosols; Bacteriophages; Chemistry, Pharmaceutical; Dry Powder Inhalers; Excipients; Humans; Lactose; Leucine; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Trehalose | 2017 |
Bacterial Clearance Is Enhanced by α2,3- and α2,6-Sialyllactose via Receptor-Mediated Endocytosis and Phagocytosis.
Topics: Animals; Disease Models, Animal; Humans; Immunologic Factors; Lactose; Male; Mice, Inbred BALB C; Models, Biological; Phagocytosis; Pseudomonas Infections; THP-1 Cells; Treatment Outcome | 2019 |
A Biomimetic Non-Antibiotic Approach to Eradicate Drug-Resistant Infections.
Topics: A549 Cells; Abscess; Adhesins, Bacterial; Animals; Biofilms; Biomimetic Materials; Drug Resistance, Bacterial; Escherichia coli; Gold Compounds; Humans; Hyperthermia, Induced; Lactose; Lectins; Mice; Mice, Inbred BALB C; Nanotubes; NIH 3T3 Cells; Phototherapy; Pneumonia, Bacterial; Polymethacrylic Acids; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
TOPICAL CHEMOTHERAPY IN PREVENTION OF WOUND INFECTION.
Topics: Animals; Bacitracin; Escherichia coli Infections; Guinea Pigs; Lactose; Neomycin; Polymyxins; Powders; Proteus Infections; Pseudomonas Infections; Research; Staphylococcal Infections; Wound Infection | 1963 |
Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Burns; Ciprofloxacin; Drug Compounding; Excipients; Female; Lactose; Liposomes; Methylcellulose; Mice; Mice, Inbred BALB C; Nucleotides; Oxazines; Pseudomonas Infections; Survival Analysis; Wound Infection | 2004 |